Investor Get First Look at Starz / Liberty Media Valuation; Maxim Sees Upside (LMCA) (LMCAC) (STRZA)
Tweet Send to a FriendGet Alerts LMCA Hot Sheet
Price: $126.20 +0.60%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade LMCA Now!
Investors following the Liberty Media's / Starz (Nasdaq: LMCA) spinoff should be aware of the following changes. Non-Starz assets are now trading on a when-issued basis under the ticker LMCAV (Nasdaq: LMCAV), currently valued at $107.7. LMCA currently trades $121.3. This gives Starz an approximate value of $14.
Following the spinoff, Maxim Group thinks Starz, soon to trade under ticker STRZA (Nasdaq: STRAZ), will begin to move higher. They set a price target of $21 on the stock. They have a price target of $149 on LMCAV, down from $155. Both are Buy-rated.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Following the spinoff, Maxim Group thinks Starz, soon to trade under ticker STRZA (Nasdaq: STRAZ), will begin to move higher. They set a price target of $21 on the stock. They have a price target of $149 on LMCAV, down from $155. Both are Buy-rated.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive
- Goldman Sees Blockbuster Potential for Bristol-Myers Squibb's (BMY) Nivolumab (PD-1)
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Trader TalkRelated Entities
Maxim GroupLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

